SCHEMBL5359592

SCHEMBL5359592

CC(C)(C)C[C@H](Nc1nccc2ccccc12)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.51
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 2/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
GRN P28799 1/20 0.41
SORT1 Q99523 1/20 0.41
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
LMNA P02545 2/20 0.39
CNR2 P34972 1/20 0.38
NPC1 O15118 1/20 0.38
KRAS P01116 1/20 0.37
SOS1 Q07889 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
ITGB1 P05556 1/20 0.37
ITGA4 P13612 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359587 1.00 FDPS (0.51) FDPSALDH1A1RAB9ACYP3A4TSHR
SCHEMBL5367817 0.83 FDPS (0.52) FDPSALDH1A1RAB9AGRNSORT1
SCHEMBL6623378 0.78 FDPS (0.58) FDPSALDH1A1RAB9ACYP3A4TSHR
SCHEMBL6623376 0.78 FDPS (0.58) FDPSALDH1A1RAB9ACYP3A4TSHR
SCHEMBL5365052 0.75 P2RY1 (0.40) ALDH1A1RAB9AGRNSORT1NPC1
SCHEMBL5372372 0.74 EPAS1 (0.48) ALDH1A1GRNSORT1LMNAMME
SCHEMBL5361351 0.74 CCNA2 (0.43) ALDH1A1RAB9ANPC1ACE
SCHEMBL5365086 0.74 ALDH1A1 (0.47) ALDH1A1TSHRGRNSORT1LMNA
SCHEMBL6496216 0.74 ALDH1A1 (0.47) ALDH1A1TSHRGRNSORT1LMNA
SCHEMBL7416537 0.74 APP (0.50) ALDH1A1TSHRGRNSORT1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307095-B2 Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide IRM LLC (BM) 2007-12-11 US claimed
US-20070123523-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2007-05-31 US claimed
US-7173051-B2 Inhibitors of cathepsin S IRM, LLC (BM) 2007-02-06 US claimed
US-20050049244-A1 Inhibitors of cathepsin S IRM LLC (BM) 2005-03-03 US claimed
WO-2004112709-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2004-12-29 WO claimed
US-7307095-B2 Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide IRM LLC (BM) 2007-12-11 US disclosed
US-20070123523-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2007-05-31 US disclosed
US-7173051-B2 Inhibitors of cathepsin S IRM, LLC (BM) 2007-02-06 US disclosed
US-20050049244-A1 Inhibitors of cathepsin S IRM LLC (BM) 2005-03-03 US disclosed
WO-2004112709-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049244-A1 Inhibitors of cathepsin S CTSS, CTSB, CTSZ FDPS 2090/4885ALDH1A1 3512/4885RAB9A 905/4885
US-20070123523-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ FDPS 2090/4885ALDH1A1 3512/4885RAB9A 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.